Sohm Inc. (SHMN)
OTC PINK OTC PINK Primary 
SOHM, Inc. Announce Dr. Wei Zhu Onboard as Senior Marketing and Sales Consultant
CHINO HILLS, CA / ACCESSWIRE / November 20, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has appointed Dr. Wei Zhu as its Senior Marketing and Sales Consultant for its biotech ABBIE division. Mr. Baron Night, CEO of SOHM Inc., is pleased to announce the appointment of Dr. Wei Zhu as the company's Senior Marketing and Sales Consultant, effective immediately.
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (特許庁, Tokkyochō, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes
For Pharmaceutical, Nutraceutical, Cosmeceutical & Strategic Partnered Products CHINO HILLS, CA / ACCESSWIRE / November 14, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today receipt of the Official Notice Of Patent Allowance from Japan's Patent Office (特許庁Tokkyochō, JPO). SOHM Inc's Japanese Patent No.
SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
CHINO HILLS, CA / ACCESSWIRE / October 2, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has filed new provisional patent application with USPTO. Dr. David Aguilar, COO, SOHM, Inc. announced that the company has filed a new provisional application entitled; "DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING" Dr. Aguilar further added that the application describes specific combinations of guide RNAs used with the ABBIE system for increased targeting and efficiency of the ABBIE system.
SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders
CHINO HILLS, CA / ACCESSWIRE / September 25, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has received ABBIE Technology kits pre-launch orders. Dr. David Aguilar, COO, shared that the company has received pre-launch and pre-orders for our ABBIE technology kits.
SOHM, Inc., Announce Dr. Tetsuya Kawamura Ph. D. Joined as a Cell Engineer and Biochemist
CHINO HILLS, CA / ACCESSWIRE / August 2, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced today the appointment of Dr. Tetsuya Kawamura, Ph.D., as a Cell Engineer and Biochemist.
SOHM, Inc. has signed the Manufacturing and Supply of Skincare Topical Products with New Export Customers
CHINO HILLS, CA / ACCESSWIRE / July 30, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today the dispatch of its first initial purchase order for manufacturing and supplying skincare products to a new Far East customer. The products, which include human prescription topical treatments for skin care, acne, exfoliation, and anti-aging, will be exported to Far Eastern countries.
SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University
CHINO HILLS, CA / ACCESSWIRE / July 25, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnologycompany that manufactures and markets generic drugs covering numerous treatment categories, announced that it has signed a new agreement with Standford University. In an exciting development, SOHM announces a groundbreaking collaboration of ABBIE Technology with Stanford University, one of the world's leading research institutions.
SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell immunotherapy from a Healthy Human Donor
CHINO HILLS, CA / ACCESSWIRE / June 10, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego.
